Amgen (AMGN) Stock Slides as Market Rises: Facts to Know Before You Trade

Amgen (AMGN) stock closed down 1.22% at $280.19, significantly underperforming the broader market and the Medical sector over the past month. Ahead of its upcoming earnings report, analysts project a Q1 EPS decline of 10.22% year-over-year to $5.01, despite an anticipated 5.04% revenue increase to $8.93 billion and positive annual growth forecasts. While Amgen holds a Zacks Rank of #3 (Hold) and trades at a Forward P/E of 13.44, representing a discount to the industry average, its PEG ratio of 2.46 is higher than the industry's 1.75, indicating a mixed valuation outlook for the biotech giant.

Analysis

Amgen (AMGN) is demonstrating significant near-term underperformance, closing down 1.22% against a rising market and lagging both the S&P 500 and the broader Medical sector by a considerable margin over the past month with a 1.59% decline. The market's focus is now squarely on the upcoming earnings report, which presents a mixed outlook. Analysts forecast a 10.22% year-over-year decline in earnings per share to $5.01, suggesting potential margin compression or unfavorable base effects. This is contrasted with an expected 5.04% increase in quarterly revenue to $8.93 billion. Looking at the full year, consensus estimates are more constructive, projecting annual growth of 6.35% for earnings and 6.58% for revenue. From a valuation perspective, Amgen trades at a forward P/E ratio of 13.44, a notable discount to its industry's average of 22.21. However, its PEG ratio of 2.46 is less attractive than the industry average of 1.75, indicating that its expected earnings growth may not be as robust relative to its price. The neutral Zacks Rank of #3 (Hold) and a minor 0.54% upward revision in the consensus EPS estimate over the past month encapsulate this conflicting picture of short-term earnings pressure against a potentially undervalued long-term profile.

Key Decisions for Investors

• Investors should exercise caution ahead of the upcoming earnings release, as the forecasted 10.22% year-over-year decline in quarterly EPS could trigger further stock price volatility despite a positive annual outlook.
• While the stock's forward P/E of 13.44 appears attractive relative to its industry, the higher-than-average PEG ratio of 2.46 warrants scrutiny, suggesting the market is pricing in slower growth.
• Given the neutral 'Hold' rating and conflicting data points, it is prudent to await the earnings report for clarity on profit margins and management's guidance before adjusting positions.